Kripthonite Therapeutics ApS

CVR 43770209 · Private limited company (ApS) · Active · Low risk

Kripthonite Therapeutics ApS is a Private limited company (ApS), founded on , based in Aarhus N. The company is registered in the industry fremstilling af farmaceutiske præparater. Our model estimates a bankruptcy risk of 0.5% over the next 12 months, which is 0.4 times the average for Danish companies. 3 annual reports have been published. The latest annual report (31 Dec 2025) shows equity of DKK 4.6m and a net result of DKK -3.9m. CEO: Jan Stenvang.

Bankruptcy risk for Kripthonite Therapeutics ApS

0.5%
probability of bankruptcy within 12 months
Low risk

0.4 × the average (1.41%) · higher risk than 60% of active Danish companies

Lowest riskHighest risk

Increases the risk

CEO changes in the last year2+ · bankruptcy rate 18.5%2.1×
Return on assets< -20% · bankruptcy rate 16.7%1.9×
Time since new CEO0.5–1 yrs · bankruptcy rate 15.6%1.8×
Time at current address1 yrs · bankruptcy rate 14.0%1.6×
Age (years)3–5 yrs · bankruptcy rate 13.3%1.5×
Moves in the last 2 years1 · bankruptcy rate 12.7%1.4×
Published annual reports3–5 · bankruptcy rate 11.7%1.3×
CEO's other companies0 · bankruptcy rate 10.9%1.2×

Reduces the risk

Current ratio500%+ · bankruptcy rate 1.5%0.17×
Equity vs. share capital5+× · bankruptcy rate 2.5%0.28×
Auditor's statementExtended review · bankruptcy rate 2.9%0.33×
Equity ratio60%+ · bankruptcy rate 3.3%0.38×
Number of auditors (historical)2 · bankruptcy rate 4.6%0.52×
Auditor resigned in the last yearYes · bankruptcy rate 4.6%0.52×
Auditor registered in CVRYes · bankruptcy rate 4.8%0.55×
Audit opted outNo · bankruptcy rate 4.8%0.55×

The factors show how often companies with the same characteristic went bankrupt compared with the average (“lift”). The risk is a statistical estimate from a model trained on 141,000+ Danish bankruptcies (AUC 0.93) – not a credit rating. Read about the method.

Company details

CVR number
43770209
Status
Active
Company type
Private limited company (ApS)
Founded
(3 years)
Address
Palle Juul-Jensens Boulevard 82
8200 Aarhus N
Municipality
Aarhus
Industry
Fremstilling af farmaceutiske præparater (212000)
Bankruptcies in the industry: Fremstilling af farmaceutiske præparater
Share capital
DKK 48k
Auditor
Sønderup Godkendt Revisionsaktieselskab
Audit opted out
No

Warning signs

Annual reports filed late0 of 3
Missing annual reportNo
Negative equityNo
Equity ratio95.9%
Current ratio2,450%
Moves (last 2 years)1
CEO changes in total2
CEO's previous bankruptcies0
Other companies at the address20
Going-concern uncertaintyNo

Financials and key figures

Financial year20252024
Gross profitDKK -3.5mDKK 125k
Net profitDKK -3.9mDKK -32
EquityDKK 4.6mDKK 35k
Total assetsDKK 4.8mDKK 169k
CashDKK 3.5m–
Short-term debtDKK 195k–
Avg. employees1–

Latest annual report: Reporting class B · auditor's statement: Erklæring om udvidet gennemgang · Sønderup Godkendt Revisionsaktieselskab.

Filed annual reports

Reporting periodPublishedDays after period end
1 Jan 2025 – 31 Dec 202586
1 Jan 2024 – 31 Dec 2024151
10 Jan 2023 – 31 Dec 2023135

The annual report must reach the Danish Business Authority no later than 5 months after the end of the financial year. We mark reports published more than 6 months after as “late”.

Management, owners and auditor

RoleNameFromTo
CEOJan StenvangCurrent
CEOErik Vinther
BoardThomas Bjørnskov PoulsenCurrent
BoardKristian Mark JacobsenCurrent
BoardPer HjerrildCurrent
BoardErik VintherCurrent
BoardCarsten GrøhnCurrent
BoardPeter Horn Møller
BoardPeter Horn Møller
BoardSøren Bregenholt Frederiksen
Owner (20%)Marigold Innovation ApSCurrent
Owner (20%)Thomas B. Poulsen Holding ApSCurrent
Owner (20%)Hjerrild Chemistry Consulting ApSCurrent
Owner (20%)Jacobsen Biotech ApSCurrent
Owner (15%)Marigold Maturation Fund K/SCurrent
Owner (25%)Marigold Innovation ApS
Owner (25%)Thomas B. Poulsen Holding ApS
Owner (25%)Hjerrild Chemistry Consulting ApS
Owner (25%)Jacobsen Biotech ApS
Owner (5%)Marigold Maturation Fund K/S
Owner (10%)Marigold Maturation Fund K/S
AuditorSønderup Godkendt RevisionsaktieselskabCurrent
AuditorSønderup I/S, statsautoriserede revisorer
FounderMarigold Innovation ApSCurrent
FounderThomas B. Poulsen Holding ApSCurrent
FounderHjerrild Chemistry Consulting ApSCurrent
FounderJacobsen Biotech ApSCurrent

The CEOs' other companies

Jan Stenvang – 1 other companies

Erik Vinther – 1 other companies

Address history (1 moves)

Palle Juul-Jensens Boulevard 82, 8200 Aarhus N
c/o Marigold Innovation ApS, Agern Alle 24, 2970 Hørsholm

Other companies at the same address

Similar companies in Aarhus

Questions and answers about Kripthonite Therapeutics ApS

Has Kripthonite Therapeutics ApS gone bankrupt?

No, Kripthonite Therapeutics ApS is not registered as bankrupt in the CVR register. Its status is: active.

What is the bankruptcy risk of Kripthonite Therapeutics ApS?

Our model estimates a bankruptcy risk of 0.5% over the next 12 months (low risk), which is 0.4 times the average for Danish companies.

Who is the CEO of Kripthonite Therapeutics ApS?

Jan Stenvang is the CEO of Kripthonite Therapeutics ApS.

Who is the auditor of Kripthonite Therapeutics ApS?

Kripthonite Therapeutics ApS most recently used Sønderup Godkendt Revisionsaktieselskab.

When was Kripthonite Therapeutics ApS founded?

Kripthonite Therapeutics ApS was founded on 10 January 2023.

What is the equity of Kripthonite Therapeutics ApS?

Equity was DKK 4.6m according to the annual report for the period ending 31 December 2025.

Source: the CVR register and annual reports published by the Danish Business Authority. The information is updated continuously.